Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy.

Zhou M, Guan W, Walker LD, Mezencev R, Benigno BB, Gray A, Fernández FM, McDonald JF.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2262-71. doi: 10.1158/1055-9965.EPI-10-0126. Epub 2010 Aug 10.

2.

Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals.

Hocker JR, Bishop EA, Lightfoot SA, Lerner MR, Peyton MD, Brackett DJ, Hanas RJ, McMeekin DS, Walker JL, Hanas JS.

Cancer Invest. 2012 Feb;30(2):189-97. doi: 10.3109/07357907.2011.636115. Epub 2011 Dec 7.

PMID:
22149058
3.

Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry.

Zhang T, Wu X, Yin M, Fan L, Zhang H, Zhao F, Zhang W, Ke C, Zhang G, Hou Y, Zhou X, Lou G, Li K.

Clin Chim Acta. 2012 May 18;413(9-10):861-8. doi: 10.1016/j.cca.2012.01.026. Epub 2012 Jan 30.

PMID:
22309680
4.

Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.

Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7.

5.

Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.

Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW.

J Natl Cancer Inst. 2001 Oct 3;93(19):1458-64.

6.
7.

[Study for drug-resistance of epithelial ovarian cancer by serum protein profiling].

Zhang WY, Zhu LR, Zheng YH, Zhou L, Zhang JZ, Wu JH, Liao QP.

Zhonghua Yi Xue Za Zhi. 2009 May 19;89(19):1326-9. Chinese.

PMID:
19615186
8.

Serum proteomic pattern analysis for early cancer detection.

Liu Y.

Technol Cancer Res Treat. 2006 Feb;5(1):61-6.

PMID:
16417403
9.

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A.

Gynecol Oncol. 2008 Sep;110(3):374-82. doi: 10.1016/j.ygyno.2008.04.041. Epub 2008 Jun 27.

PMID:
18584856
10.

Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer.

Urayama S, Zou W, Brooks K, Tolstikov V.

Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):613-20. doi: 10.1002/rcm.4420.

PMID:
20143319
11.

Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.

Kong F, Nicole White C, Xiao X, Feng Y, Xu C, He D, Zhang Z, Yu Y.

Gynecol Oncol. 2006 Feb;100(2):247-53. Epub 2005 Oct 17.

PMID:
16229881
12.

Serum proteomic patterns for ovarian cancer monitoring.

Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, Berns EM.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95. Epub 2007 Nov 20.

PMID:
18028381
13.

Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer.

Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, Gye-Hyun N, Young-Lae C, Ho-Sun C, Heung-Jae J, Chong-Kook K, Young-Wan K, Byoung-Don H, Hyun-Sun J.

Cancer Sci. 2005 Mar;96(3):197-201.

14.

Proteomic studies of early-stage and advanced ovarian cancer patients.

Wang J, Zhang X, Ge X, Guo H, Xiong G, Zhu Y.

Gynecol Oncol. 2008 Oct;111(1):111-9. doi: 10.1016/j.ygyno.2008.06.031. Epub 2008 Aug 15.

PMID:
18703221
15.

Mass spectrometric analysis of protein markers for ovarian cancer.

Wang Z, Yip C, Ying Y, Wang J, Meng XY, Lomas L, Yip TT, Fung ET.

Clin Chem. 2004 Oct;50(10):1939-42. No abstract available.

16.

Diagnostic markers for early detection of ovarian cancer.

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.

Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308. Clin Cancer Res. 2008 Nov 1;14(21):7158.

17.

Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer.

Oh JH, Nandi A, Gurnani P, Knowles L, Schorge J, Rosenblatt KP, Gao JX.

J Bioinform Comput Biol. 2006 Dec;4(6):1159-79.

PMID:
17245808
18.

Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma.

Olejek A, Damasiewicz-Bodzek A, Bodzek P, Wielkoszyński T, Zamłyński J, Stołtny P, Skutil M.

Int J Gynecol Cancer. 2009 Dec;19(9):1516-20. doi: 10.1111/IGC.0b013e3181bf425b.

PMID:
19955928
19.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

20.

Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.

Callesen AK, Madsen JS, Iachina M, Vach W, Kruse TA, Jensen ON, Mogensen O.

Cancer Biomark. 2010;6(2):73-82. doi: 10.3233/CBM-2009-0120.

PMID:
20571233
Items per page

Supplemental Content

Write to the Help Desk